Replies to post #192176 on Biotech Values

[mcbio]

AAVL

Using Hammer’s definition of success—and adding the requirement that there are no troubling safety issues—my probability of success is less than 50%. (No position.)

No position for me either but am certainly anxious to see the data and resulting stock reaction. I think if the results show that one shot isn't going to be enough but the drug otherwise shows it can meaningfully reduce the number of shots needed (compared to Lucentis) and shares tank, I think AAVL could be worth a look.